Legal basis: Drug Administration Law of People's Republic of China (PRC).
Article 1 This Law is formulated with a view to strengthening drug supervision and administration, ensuring drug quality, ensuring the safety of human drug use, and safeguarding people's health and the legitimate rights and interests of drug use.
Article 2 Units or individuals engaged in drug research, production, trading, use, supervision and management within the territory of People's Republic of China (PRC) must abide by this Law.
Article 3 The state develops modern medicine and traditional medicine and gives full play to their roles in prevention, medical treatment and health care.
The state protects wild medicinal resources and encourages the cultivation of Chinese medicinal materials.
Article 4 The State encourages the research and development of new drugs and protects the legitimate rights and interests of citizens, legal persons and other organizations in the research and development of new drugs.
Article 5 The drug supervision and administration department of the State Council is in charge of drug supervision and administration throughout the country. The relevant departments of the State Council are responsible for drug supervision and administration within their respective functions and duties. The pharmaceutical supervisory and administrative departments of the people's governments of provinces, autonomous regions and municipalities directly under the Central Government shall be responsible for the pharmaceutical supervisory and administrative work within their respective administrative areas. The relevant departments of the people's governments of provinces, autonomous regions and municipalities directly under the Central Government shall be responsible for drug supervision and administration within their respective functions and duties. The drug supervision and administration department of the State Council shall cooperate with the comprehensive economic department of the State Council to implement the development plan and industrial policy of the pharmaceutical industry formulated by the state.